LY-2365109
A detailed overview of the investigational drug LY-2365109
LY-2365109 is an investigational drug that has been studied for its potential effects on the central nervous system. It is primarily known for its action as a selective antagonist of the metabotropic glutamate receptor subtype 2 (mGluR2). This receptor is involved in modulating synaptic transmission and is implicated in various neurological and psychiatric disorders.
Mechanism of Action[edit | edit source]
LY-2365109 functions by selectively inhibiting the mGluR2 receptor. The mGluR2 receptor is a G-protein coupled receptor that plays a role in the regulation of glutamate, the primary excitatory neurotransmitter in the brain. By antagonizing this receptor, LY-2365109 may alter glutamatergic signaling, which is thought to be beneficial in conditions characterized by excessive glutamate activity, such as schizophrenia and anxiety disorders.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of LY-2365109 has been studied in preclinical models. It is known to have a moderate half-life and is metabolized primarily in the liver. The drug is administered orally and has been shown to cross the blood-brain barrier, which is essential for its action on central nervous system targets.
Clinical Trials[edit | edit source]
As of the latest updates, LY-2365109 has undergone several phases of clinical trials. Early-phase trials have focused on its safety, tolerability, and pharmacokinetics in healthy volunteers. Subsequent trials have explored its efficacy in patients with schizophrenia and other psychiatric disorders. Results have shown promise, but further studies are needed to fully establish its therapeutic potential and safety profile.
Potential Therapeutic Uses[edit | edit source]
LY-2365109 is being investigated for its potential use in treating:
- Schizophrenia: Due to its action on mGluR2, it may help in managing symptoms associated with this disorder.
- Anxiety disorders: Its ability to modulate glutamatergic transmission could be beneficial in reducing anxiety symptoms.
- Depression: There is ongoing research into its effects on mood regulation.
Side Effects[edit | edit source]
The side effect profile of LY-2365109 is still being characterized. Commonly reported side effects in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. Long-term safety data are not yet available.
Research and Development[edit | edit source]
LY-2365109 is developed by Eli Lilly and Company, a pharmaceutical company known for its research in neuroscience. The development of LY-2365109 is part of a broader effort to create novel treatments for psychiatric and neurological disorders by targeting glutamatergic pathways.
Also see[edit | edit source]
- Metabotropic glutamate receptor
- Glutamate (neurotransmitter)
- Schizophrenia
- Anxiety disorder
- Eli Lilly and Company
| Receptor Antagonists | |
|---|---|
| Receptor Type | Example Antagonists |
| Adrenergic receptor | Propranolol, Prazosin |
| Cholinergic receptor | Atropine, Scopolamine |
| Dopamine receptor | Haloperidol, Clozapine |
| Histamine receptor | Ranitidine, Diphenhydramine |
| Serotonin receptor | Ondansetron, Risperidone |
| Glutamate receptor | Memantine, Ketamine |
| GABA receptor | Flumazenil, Bicuculline |
| Opioid receptor | Naloxone, Naltrexone |
| Angiotensin receptor | Losartan, Valsartan |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
